AR101060A1 - Conjugados de fviii - Google Patents

Conjugados de fviii

Info

Publication number
AR101060A1
AR101060A1 ARP150100398A ARP150100398A AR101060A1 AR 101060 A1 AR101060 A1 AR 101060A1 AR P150100398 A ARP150100398 A AR P150100398A AR P150100398 A ARP150100398 A AR P150100398A AR 101060 A1 AR101060 A1 AR 101060A1
Authority
AR
Argentina
Prior art keywords
heparosan polymer
factor viii
formula
conjugate
reactive amine
Prior art date
Application number
ARP150100398A
Other languages
English (en)
Inventor
Dr Haller Michael
Dr Deangelis Paul
Behrens Carsten
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of AR101060A1 publication Critical patent/AR101060A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicación 1: Un conjugado que comprende un polipéptido del Factor VIII, un resto conector y un polímero de heparosano, donde el resto conector entre el polipéptido del Factor VIII y el polímero de heparosano comprende X tal como se indica a continuación: [polímero de heparosano] - [X] - [Factor VIII] donde X comprende un derivado de ácido siálico que está conectado a un resto de acuerdo con la fórmula (1). Reivindicación 11: Una composición farmacéutica que comprende un conjugado de acuerdo con cualquiera de las reivindicaciones anteriores. Reivindicación 15: Un método para conjugar un polímero de heparosano con un polipéptido del FVIII que comprende los siguientes pasos: (i) hacer reaccionar un polímero de heparosano que comprende una amina reactiva [HEP-NH] con un ácido 4-formilbenzoico activado para obtener el compuesto de fórmula (2), donde dicha amina reactiva se puede unir directamente al polímero heparosano o se puede unir a través de un resto conector que conecte la amina reactiva con dicho polímero de heparosano, (ii) hacer reaccionar el compuesto de fórmula (2) con un derivado de ácido siálico activado con CMP en condiciones reductoras, (iii) conjugar el compuesto obtenido en el paso ii) con un polipéptido del Factor VIII.
ARP150100398A 2014-02-12 2015-02-11 Conjugados de fviii AR101060A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14154876 2014-02-12

Publications (1)

Publication Number Publication Date
AR101060A1 true AR101060A1 (es) 2016-11-23

Family

ID=50071544

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150100398A AR101060A1 (es) 2014-02-12 2015-02-11 Conjugados de fviii

Country Status (14)

Country Link
US (2) US20150224203A1 (es)
EP (1) EP3104893A1 (es)
JP (1) JP2017507135A (es)
KR (1) KR20160120296A (es)
CN (1) CN105979972A (es)
AR (1) AR101060A1 (es)
AU (1) AU2015216985A1 (es)
BR (1) BR112016018224A2 (es)
CA (1) CA2939441A1 (es)
IL (1) IL246713A0 (es)
MX (1) MX2016010231A (es)
RU (1) RU2016134357A (es)
TW (1) TW201613650A (es)
WO (1) WO2015121382A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR099340A1 (es) * 2014-02-12 2016-07-13 Novo Nordisk As Conjugados del factor de coagulación ix
KR20190086269A (ko) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 체내 지속형 재조합 당단백질 및 이의 제조방법
WO2020086686A2 (en) * 2018-10-23 2020-04-30 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor viii function
KR101964405B1 (ko) 2018-12-17 2019-04-01 영동이앤지(주) 교량 받침의 연단거리 측정점검 장치

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7211558B2 (en) * 2002-05-22 2007-05-01 The Children's Hospital Of Philadelphia Compositions and methods for the treatment of hemophilia A
US20090048440A1 (en) * 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
MX2010009154A (es) * 2008-02-27 2010-09-09 Novo Nordisk As Moleculas conjugadas del factor viii.
US9687559B2 (en) * 2008-03-19 2017-06-27 The Board Of Regents Of The University Of Oklahoma Heparosan polymers and methods of making and using same for the enhancement of therapeutics
WO2010030342A2 (en) * 2008-09-09 2010-03-18 The Board Of Regents Of The University Of Oklahoma Heparosan polymers and methods of making and using same for the enhancement of therapeutics
CN102770449B (zh) * 2010-02-16 2016-02-24 诺沃—诺迪斯克有限公司 具有降低的vwf结合的因子viii分子
US20150080309A1 (en) * 2012-04-24 2015-03-19 Nova Nordisk A/S Compounds Suitable for Treatment of Haemophilia
US20150045303A1 (en) * 2012-04-24 2015-02-12 Novo Nordisk A/S Pharmaceutical Composition Suitable for Treatment of Haemophilia
JP2016510984A (ja) * 2013-03-12 2016-04-14 ノヴォ ノルディスク アー／エス トロンビン感受性凝固第ｘ因子分子
CN105637088A (zh) * 2013-10-15 2016-06-01 诺和诺德保健股份有限公司 凝固因子vii多肽

Also Published As

Publication number Publication date
RU2016134357A (ru) 2018-03-16
US20160120953A1 (en) 2016-05-05
KR20160120296A (ko) 2016-10-17
CN105979972A (zh) 2016-09-28
JP2017507135A (ja) 2017-03-16
AU2015216985A1 (en) 2016-07-28
EP3104893A1 (en) 2016-12-21
MX2016010231A (es) 2016-10-13
BR112016018224A2 (pt) 2017-10-17
CA2939441A1 (en) 2015-08-20
WO2015121382A1 (en) 2015-08-20
US20150224203A1 (en) 2015-08-13
TW201613650A (en) 2016-04-16
IL246713A0 (en) 2016-08-31

Similar Documents

Publication Publication Date Title
UY36186A (es) Ácidos grasos novedosos y su uso en la conjugación con biomoléculas
CY1121225T1 (el) Συμπυκνωμενες iμιδαζολυλιμιδαζολες ως αντιiκες ενωσεις
PE20160665A1 (es) Derivados 11-hidroxilo de acidos biliares y conjugados de aminoacidos de los mismos como moduladores del receptor de farnesoid x
MX2021004884A (es) Conjugado anticuerpo anti-factor de crecimiento epidermico humano 3 (anti-her3-farmaco).
CO7111284A2 (es) Nucleósidos de espirooxetano de uracilo
BR112015027321A2 (pt) composições e métodos
BR112014032809A2 (pt) melhora de autofagia ou aumento de longevidade pela administração de urolitinas ou precursores das mesmas
CR20110688A (es) Conjugados de hidrocodona con ácido benzoico, derivados de ácido benzoico y ácido carboxílico heteroarílico, profárcos, métodos de preparación y uso de los mismos
PH12015501843A1 (en) Novel pyrazol derivatives
CO6690768A2 (es) Derivados de triazina-oxadiazoles, útiles como inhibidores de los canales de sodio navi.7
BR112015012919A2 (pt) novos derivados de piridina
PH12015501073A1 (en) Novel pyridine derivatives
AR101060A1 (es) Conjugados de fviii
BR112012030473A2 (pt) pesticidas baseados em derivados pirrolidina espiroheterocíclicos
PH12015501933A1 (en) Novel pyridine derivatives
BR112015009603A2 (pt) novos derivados de pirazina
SV2018005760A (es) Derivados de aminotiazol utiles como agentes antiviricos
BR112014012458A2 (pt) processo para o preparo de derivados de esterol
AR099328A1 (es) Conjugados de factor vii
BR112014019220A8 (pt) Novos derivados de pirrolidina
BR112015026048A2 (pt) análogos de combretastatina
MX2011011716A (es) Derivados de isoquinolina novedosos.
BR112015030824A2 (pt) novos derivados de tetrazolona
AR098023A1 (es) Un proceso para preparar isoxaflutol
CY1120482T1 (el) Μεθοδος συνθεσης 3,4-διμεθοξυδικυκλο[4.2.0]οκτα-1,3,5-τριενο-7-καρβονιτριλιου και εφαρμογη στη συνθεση της ιβαμπραδινης και των αλατων προσθηκης αυτης με ενα φαρμακευτικως αποδεκτο οξy

Legal Events

Date Code Title Description
FB Suspension of granting procedure